Journal: International Dental Journal

Article Title: 4632427E13Rik Facilitates Jaw Marrow-Derived Mesenchymal Stem Cells Osteogenesis and Angiogenesis Under Hypoxia Through miR-34a-5p/Aldoa/Hif-1α Pathway

doi: 10.1016/j.identj.2025.109364

Figure Lengend Snippet: Aldoa promotes osteogenesis and angiogenesis via the ERK/Hif-1α pathway. A, Alizarin red staining (14 days) and ALP staining (7 days). B, The gene expression levels of Runx2, Alp and Ocn were determined by qRT-PCR. β-actin was used as an internal reference gene. C, Tube formation assay was performed in the presence of CM. The scale bars represent 100 μm. D, The mRNA expression levels of Vegf and CD31 were analysed by quantitative RT-PCR. β-actin was used as an internal reference gene. E, Immunofluorescence staining was performed to detect Vegf expression after being treated by CM. The scale bars represent 25 μm. F, A Kyoto Encyclopaedia of Genes and Genomes (KEGG) enrichment analysis was performed to determine the top related pathways involving these differentially expressed mRNAs. G and H, The protein expression levels of Aldoa, Hif-1α and the phosphorylated of ERK, JUK and p38 among hypoxia, normoxia and hypoxia + si-Aldoa groups were determined by western blot. Semiquantitative analysis of the p-ERK/ERK, p-JUK/JUK and p38/p-p38 ratios were shown. β-actin was used as an internal reference gene. All data were expressed as means ± SD. * P < .05, ** P < .01.

Article Snippet: Rabbit anti-Aldoa (1:1000, 11217-1-AP), rabbit anti-Hif-1α (1:1000, ab179483), rabbit anti-Runx2 (1:1000, 8486S), rabbit anti-CD31 (1:1000, 77699S), rabbit anti-Ocn (1:1000, bs-4917R), rabbit anti-Alp (1:1000, bs-1535R), rabbit anti-Vegf (1:1000, bs-1313R), rabbit anti-ERK (1:1000, bsm-33337M), rabbit anti-p-ERK (1:1000, bs-1646R), rabbit anti-p38 (1:1000, bs-0637R), rabbit anti-p-p38 (1:1000, bs-0636R), rabbit anti-JNK (1:1000, bs-2592R), rabbit anti-p-JNK (1:1000, bs-1640R), and mouse anti-β-actin (1:2000, AF7018) were purchased from Proteintech, Abcam, Cell Signalling Technology, and Bioss, respectively.

Techniques: Staining, Gene Expression, Quantitative RT-PCR, Tube Formation Assay, Expressing, Immunofluorescence, Western Blot

Journal: International Dental Journal

Article Title: 4632427E13Rik Facilitates Jaw Marrow-Derived Mesenchymal Stem Cells Osteogenesis and Angiogenesis Under Hypoxia Through miR-34a-5p/Aldoa/Hif-1α Pathway

doi: 10.1016/j.identj.2025.109364

Figure Lengend Snippet: Aldoa promotes osteogenesis and angiogenesis via the ERK/Hif-1α pathway. A, Alizarin red staining (14 days) and ALP staining (7 days). B, The gene expression levels of Runx2, Alp and Ocn were determined by qRT-PCR. β-actin was used as an internal reference gene. C, Tube formation assay was performed in the presence of CM. The scale bars represent 100 μm. D, The mRNA expression levels of Vegf and CD31 were analysed by quantitative RT-PCR. β-actin was used as an internal reference gene. E, Immunofluorescence staining was performed to detect Vegf expression after being treated by CM. The scale bars represent 25 μm. F, A Kyoto Encyclopaedia of Genes and Genomes (KEGG) enrichment analysis was performed to determine the top related pathways involving these differentially expressed mRNAs. G and H, The protein expression levels of Aldoa, Hif-1α and the phosphorylated of ERK, JUK and p38 among hypoxia, normoxia and hypoxia + si-Aldoa groups were determined by western blot. Semiquantitative analysis of the p-ERK/ERK, p-JUK/JUK and p38/p-p38 ratios were shown. β-actin was used as an internal reference gene. All data were expressed as means ± SD. * P < .05, ** P < .01.

Article Snippet: Rabbit anti-Aldoa (1:1000, 11217-1-AP), rabbit anti-Hif-1α (1:1000, ab179483), rabbit anti-Runx2 (1:1000, 8486S), rabbit anti-CD31 (1:1000, 77699S), rabbit anti-Ocn (1:1000, bs-4917R), rabbit anti-Alp (1:1000, bs-1535R), rabbit anti-Vegf (1:1000, bs-1313R), rabbit anti-ERK (1:1000, bsm-33337M), rabbit anti-p-ERK (1:1000, bs-1646R), rabbit anti-p38 (1:1000, bs-0637R), rabbit anti-p-p38 (1:1000, bs-0636R), rabbit anti-JNK (1:1000, bs-2592R), rabbit anti-p-JNK (1:1000, bs-1640R), and mouse anti-β-actin (1:2000, AF7018) were purchased from Proteintech, Abcam, Cell Signalling Technology, and Bioss, respectively.

Techniques: Staining, Gene Expression, Quantitative RT-PCR, Tube Formation Assay, Expressing, Immunofluorescence, Western Blot

Journal: bioRxiv

Article Title: Targeting one-carbon metabolic vulnerabilities of metastasis with therapeutic potential

doi: 10.64898/2026.02.07.704548

Figure Lengend Snippet: ( A ) Schematic of the metastasis functional screening using molecular inhibitors in vivo. ( B, C, and D ) Gross pulmonary metastases from human melanoma A375sm (B), mouse melanoma B16F10 (C), and mouse rhabdomyosarcoma RMS14 (D) in response to molecular inhibitor in the experimental metastasis assay by tail vein injection. Data are represented as mean ± SEM. The p-values were presented from an unpaired t-test analysis (two-tailed) compared with the control (DMSO). Cal C, 100 nM calphostin C; Rho, 12nM Rho Inhibitor I; Rap, 10nM Rapamycin; H-89, 50nM PKA inhibitor; SB, 10µM p38 inhibitor SB203580; TSA, 300nM HDAC inhibitor Trichostatin A; MS, 10µM HDAC inhibitor MS-275; PD, 20µM MAPK inhibitor PD98059; LY, 10µM PI3K/AKT inhibitor LY294002. ND , no statistical difference; * p < 0.05; ** p < 0.01; *** p < 0.001. n = 10. ( E, F, and G ) The related cell viability of human melanoma A375sm (E), mouse melanoma B16F10 (F), and mouse rhabdomyosarcoma (G) cells, pretreated with molecular inhibitors. Data are represented as mean ± SEM of three independent experiments. The p-values were presented from an unpaired t-test analysis (two-tailed) compared with the control (DMSO). ND , no statistical difference; * p < 0.05; ** p < 0.01; *** p < 0.001. ( H ) Gross pulmonary metastases from mouse melanoma B16F10 pretreated with 10µM PI3K/AKT inhibitor LY294002 at the indicated time (LY12, 12 hours, LY24, 24 hours and LY48, 48 hours). Data are represented as mean ± SEM. The p-values were presented from an unpaired t-test analysis (two-tailed) compared with the control (DMSO). ND , no statistical difference; * p < 0.05; ** p < 0.01; *** p < 0.001. n=10. ( I ) Gross pulmonary metastases from mouse rhabdomyosarcoma RMS14 cells pretreated with 20µM MAPK inhibitor PD98059 at the indicated time (PD12, 12 hours, PD24, 24 hours and PD48, 48 hours). Data are represented as mean ± SEM. The p-values were presented from an unpaired t-test analysis (two-tailed) compared with the control (DMSO). ND , no statistical difference; * p < 0.05; ** p < 0.01; *** p < 0.001. n=10.

Article Snippet: Calphostin C, Rho Inhibitor I, Rapamycin, PKA inhibitor H-89, p38 inhibitor SB203580, HADC inhibitor Trichostatin A and MS-275, MAPK inhibitor PD98059, PI3K/AKT inhibitor LY294002, Rottlerin, bisindoylmaleimide I (BMI), PKC β inhibitor I, and FDA-approved-Drug-Library (1562 compounds, HY-L022) were obtained from MedChemExpress (Monmouth Junction, NJ).

Techniques: Functional Assay, In Vivo, Injection, Two Tailed Test, Control

Journal: bioRxiv

Article Title: Targeting one-carbon metabolic vulnerabilities of metastasis with therapeutic potential

doi: 10.64898/2026.02.07.704548

Figure Lengend Snippet: (A) Schematic of microarray analysis to focus on the inhibition of tumor metastasis. (B) The significant differentiated gene expression patterns associated with the inhibition of tumor metastasis progression and the identification of metabolism pathways associated with tumor metastasis. The significantly expressed genes in B16F10 (a) or RMS14 (b) cells treated with inhibitors (Cal C, 100 nM calphostin; Rap, 10nM Rapamycin; 20µM MAPK inhibitor PD98059; LY, 10µM PI3K/AKT inhibitor LY294002) compared with DMSO control were filtered by a p-value of 0.05 and an absolute value of fold change of 1.5 in ANOVA analysis. a1, Cal C v.s. DMSO; a2, Rap v.s. DMSO; a3, LY24 v.s. DMSO; a4, LY48 v.s. DMSO in B16F10 cells. b1, Cal C v.s. DMSO; b2, Rap v.s. DMSO; b3, PD24 v.s. DMSO; b4, PD48 v.s. DMSO in RMS14 cells. ( C ) Gene signaling pathway (GO gene pathway) analysis revealed that top 15 biological pathways and functions within a given gene list from micrroarry analysis regulate one-carbon metabolism and de novo serine synthesis (SSP). Both p and FDR valuest were transformed to negative log (-log2) values. ( D ) Schematic of the one-carbon metabolism and De novo serine synthesis (SSP) pathways. ( E to H ) Validation of gene expression identified in cDNA microarray analysis by Western blot analysis. The human melanoma A375sm (E) and WM88 (F), mouse melanoma B16F10 (G), or mouse rhabdomyosarcoma RMS14 (H) cells were treated with molecular inhibitors. DMSO, as a mock control; Cal C, 100 nM calphostin C; Rho, 12nM Rho Inhibitor I; Rap, 10nM Rapamycin; SB, 10 µM p38 inhibitor SB203580; PD, 20 µM MAPK inhibitor PD98059; LY, 10 µM PI3K/AKT inhibitor LY294002; Rott, 5μM of rottlerin; BMI, 20 nM of bisindoylmaleimide I; Iβ, 20 nM of PKCβ inhibitor I. β -actin was used as a control.

Article Snippet: Calphostin C, Rho Inhibitor I, Rapamycin, PKA inhibitor H-89, p38 inhibitor SB203580, HADC inhibitor Trichostatin A and MS-275, MAPK inhibitor PD98059, PI3K/AKT inhibitor LY294002, Rottlerin, bisindoylmaleimide I (BMI), PKC β inhibitor I, and FDA-approved-Drug-Library (1562 compounds, HY-L022) were obtained from MedChemExpress (Monmouth Junction, NJ).

Techniques: Microarray, Inhibition, Gene Expression, Control, Transformation Assay, Biomarker Discovery, Western Blot

Journal: bioRxiv

Article Title: Targeting one-carbon metabolic vulnerabilities of metastasis with therapeutic potential

doi: 10.64898/2026.02.07.704548

Figure Lengend Snippet: ( A ) Western blotting showed the expression of the indicated one-carbon and SSP metabolism pathway genes treated with different compounds, including identified new compounds comp4, comp7, and comp9. The cells were treated with 5 µM NCT503, 10 µM comp2, 10 µM comp3, 100 nM comp4, 10µM venetoclax, 10 µM comp6, 10 nM comp7, 30 nM CB-839, 10µM comp9, DMSO, 5 mM 2-DG, 1 mM BSO, 10 µM comp13, 10 µM comp14, 2 mM metf (Metformin) for 36 hours. ( B, C ) Seahorse analysis showed the effect of the different compounds on OCR (B) and ATP production (C). The cells were treated with 100 nM calphostin (Cal C), 10nM Rapamycin (Rap), 20µM MAPK inhibitor PD98059 (PD), 10µM PI3K/AKT inhibitor LY294002 (LY), 100 nM comp4, 5 µM NCT503, 10 nM comp7, 10µM comp9, 2 mM Metformin(Metf), 10 µM comp13, 10 µM comp14 and DMSO control. ND , no statistical difference; * p < 0.05; ** p < 0.01; *** p < 0.001. ( D, E ) Representation of bioluminescence signals of tumor metastasis from before treatment (D) and treated for two weeks with indicated compouds (E) after A375sm cell transplantation in NSG mice tracked by of the In Vivo Imaging System (IVIS). C, DMSO control; NCT503, 20 mg/Kg; Comp2, 25 mg/Kg; Comp4, 30 mg/Kg; comp7, 3 mg/Kg; comp9, 10 mg/Kg; venetoclax, 12 mg/Kg. ( F ) Gross pulmonary metastases from mice transplanted with cells by tail vein injection and treated with different compounds. N=10. Graphs show the mean ± SEM. The p-value is shown by an unpaired t-test (two-tailed). ND , no statistical difference; * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Calphostin C, Rho Inhibitor I, Rapamycin, PKA inhibitor H-89, p38 inhibitor SB203580, HADC inhibitor Trichostatin A and MS-275, MAPK inhibitor PD98059, PI3K/AKT inhibitor LY294002, Rottlerin, bisindoylmaleimide I (BMI), PKC β inhibitor I, and FDA-approved-Drug-Library (1562 compounds, HY-L022) were obtained from MedChemExpress (Monmouth Junction, NJ).

Techniques: Western Blot, Expressing, Control, Transplantation Assay, In Vivo Imaging, Injection, Two Tailed Test